Phosphocitrate, a potential therapeutic agent for calcium crystal deposition diseases

Current Rheumatology Reviews

Volumn 2, Issue 1, 2006, Pages 95-99

  Sallis, John D ^a   Demadis, Konstantinos D ^b   Cheung, Herman S ^a,c  

^a University of Miami College of Engineering   (United States)

^b UNIVERSITY OF CRETE   (Greece)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chemistry; Inhibition; Osteoarthritis; Phosphocitrate; Review; Therapeutic options

Indexed keywords

CALCIUM; CALCIUM PHOSPHATE; CALCIUM PYROPHOSPHATE; CALCIUM SALT; CELECOXIB; CITRIC ACID; HYALURONIC ACID; PHOSPHOCITRIC ACID; ROFECOXIB; UNCLASSIFIED DRUG;

CALCIFICATION; CARTILAGE DEGENERATION; CELL CULTURE; CELL DEATH; CLINICAL FEATURE; CULTURE MEDIUM; DISEASE MODEL; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; REVIEW; STRUCTURE ANALYSIS; UNSPECIFIED SIDE EFFECT;

EID: 33745891489     PISSN: 15733971     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339706775696928     Document Type: Review

References (34)

1. Meyer J, Bolen R, Stakelum IJ. The synthesis of citric acid phosphate. J Am Chem Soc 1959; 81:2094-2096.
2. Howard JE. Studies on urinary stone formation: a saga of clinical investigation. John Hopkins Med J 1976; 139:239-252.
3. Lehninger AL. Mitochondria and biological mineralization processes. Horiz Biochem Biophys 1977; 4:1-30.
4. 32P-labelled phosphocitrate and analytical systems for its identification. Anal Biochem 1980; 102:365-373.
5. Tew WP, Mahle CD, Benavides J, Howard JE, Lehninger AL. Synthesis and characterization of phosphocitirc acid, a potent inhibitor of hydroxylapatite crystal growth. Biochemistry 1980; 19:1983-1988.
6. Williams G, Sallis JD. The sources of phosphocitrate and its role as an inhibitor of calcium phosphate and calcium oxalate crystallization. In: Smith LH, Robertson WG, Finlayson B, Editors. Urolithiasis: Clinical and Basic Research. NY: Plenum Press, 1981: 569-577.
7. Sallis JD. Structure/performance relationships of phosphorous and carboxyl containing additives as calcium phosphate crystal growth inhibitors. In: Calcium phosphates in biological and industrial systems. Amjad Z, editor. Kluwer Academic Publishers, 1998: 8-17.
8. Sallis JD, Parry NF, Meehan JD, Kamperman H, Anderson ME. Controlling influence of phosphocitrate in vitro and in vivo on calcium oxalate crystal formation and growth. Scanning Microsc 1995; 9:127-135.
9. Sallis JD, Wierzbicki A, Cheung HS. Calcium pyrophosphate crystal forms and the influence of phosphocitrate. In: Amzad Z, editor. Advances in Crystal Growth and Inhibition Technologies. Philadelphia: Plenum, 2000.
10. Demadis KD, Sallis JD, Raptis RG, Baran P. A Crystallographically characterized nine-coordinated calcium-phosphocitrate complex as calcification inhibitor in vivo. J Am Chem Soc 2001; 123:10129-10130.
11. Sun Y, Reuben PM, Wenger L, Sallis JD, Demadis KD, Cheung HS. Inhibition of calcium phosphate-DNA co-precipitates-induced cell death by phosphocitrate. Frontiers in Bioscience 2005; 10:803-808.
12. Cheung HS. Biologic effects of calcium-containing crystals. Curr Opin Rheum 2005; 17:336-340.
13. Rosenthal AK RL. CPPD crystal deposition disease. In: Arthritis and Allied Conditions. WJ Koopman, Editor. Lippincott, Williams and Wilkins, 2001: 2348-2354.
14. Halverson PB. BCP crystal depositon disease and calciosis. In: Arthritis and Allied Conditions. WJ Koopman, Editor. Lippincott, Williams and Wilkins, 2001: 2372.
15. Cheung HS. Role of calcium-containing crystals in Osteoarthritis. Frontiers in Bioscience 2005; 10:1336-1340.
16. Gibilisco PA, Schumacher HR, Hollander JL, Soper KA. Synovial fluid crystals in osteoarthritis. Arthritis Rheum 1985; 28:511-515.
17. Zitnan D, Sitaz S. Natural course of articular chonodrocalcinosis. Arthritis Rheum 1976; 19:363-390.
18. Ledingham J, Regan M, Jones A, Doherty M. Factors affecting radiographic progression of knee osteoarthritis. Ann Rheum Dis 1995; 54:53-58.
19. Carroll G, Stuart RA, Armstrong JA, Breidahl PD, Lasing BA. Hydroxyapatite crystals are a freuent finding in osteoarthritic synovial fluid. J Rheumatol 1991; 18:861-866.
20. Carroll G, McCappin S, Bell M, Schwarzer A, Breidahl P. Comparison of keratan sulphate concentrations and the size distribution of proteoglycans in the synovial fluid of patients with osteoarthritis and pyrophosphate arthropathy. Rheumatol Int 1991; 11:63-68.
21. Lohmander LS, Hoerrner LA, Lark MW. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 1993; 36:181-189.
22. Cheung HS. Calcium crystal effects on the cells of the joint: Implications for pathogenesis of the disease. Curr Opin Biol 2000; 12(3):223-227.
23. Shankar R, Tuyethong N, Sallis JD. Atherogenesis: mitigation of monocyte adhesion to arterial endothelium in hyperlipidemic rats by phosphocitrate, a phosphorylated polycarboxylic acid. Atherosclerosis 1986; 52:191-198.
24. Ward L, Shankar R, Sallis JD. A possible antiatherogenic role for phosphocitrate through modulation of low density lipoprotein uptake and degradation in aortic smooth muscle cells. Atherosclerosis 1987; 65:117-124.
25. Cook MM, McCarthy GM, Sallis JD, Morgan MP. Phosphocitrate inhibits calcium hydroxyapatite induced mitogenesis and upregulation of matrix metalloproteinase-1 interleukin-1β and cyclooxygenase-2 mRNA in human breast cancer cell lines. Breast Cancer Res Treat 2003; 79:253-263.
26. Krug HE, Mahowald ML, Halverson PB, Sallis JD, Cheung HS. Phosphocitrate prevents disease progression in murine progressive ankylosis. Arthritis Rheum 1993; 36:1603-1611.
27. Cheung HS. Phosphocitrate as a potential therapeutic strategy for cystal deposition disease. Curr Rheumatol Rep 2001; 3:24-28.
28. Cheung HS, Sallis JD, Struve JA. Specific inhibition of BCP and CPPD crystal-induced collagenase and stromelysin synthesis by phosphocitrate. Biochim Biophys Acta 1996; 1315:105-111.
29. Nair D, Misra RP, Sallis JD, Cheung HS. Phosphocitrate inhibits a basic calcium phosphate and calcium pyrophosphate dihydrate crystal-induced mitogen-activated protein kinase cascade signal transduction pathway. J Biol Chem 1997; 272:18920-18925.
30. Cheung HS, Kurup IV, Sallis JD, Ryan LM. Inhibibition of CPPD crystal formation in articular cartilage vesicles and cartilage by phosphocitrate. J Biol Chem 1996; 271:28082-28085.
31. Morgan MP,Whelan LC, Sallis JD, McCarthy CJ, Fitzgerald DJ, McCarthy GM. Basic calcium phosphate crystal-induced prostaglandin E2 production in human fibroblasts: role of cyclooxygenase 1, cyclooxygenase 2, and interleukin-1beta. Arthritis Rheum 2004; 50:1642-1649.
32. 2. Proc Soc Exp Biol Med 1983; 173:181-189.
33. Sallis JD, Shanker R, Rees B, Thomson R. Protection of crystal-induced polymorphonuclear leukocyte membranolysis by phosphocitrate. Biochem Med Metabolic Biol 1989; 41:56-63.
34. Tsao JW, Schoen FJ, Shankar R, Sallis JD, Levy RJ. Retardation of calcification of bovine pericardium used in bioprosthetic heart valves by phosphocitrate and a synthetic analogue. Biomaterials 1988; 9:393-397.